GlassScriptPhysician profile
Vijaya Koka
NPI 1467436212
$5,285.34
in general payments reported to CMS, 2019-2025
28 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $807 · 2021: $1,051 · 2022: $727 · 2023: $679 · 2024: $780 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $664.66 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $630.29 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $600.95 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $496.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $388.76 | 2021-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $337.38 | 2019-2024 | |
| Boston Scientific Corporation | $258.11 | 2021-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $206.42 | 2019-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $193.93 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $186.79 | 2019-2024 | Lifevest |
| Biotronik INC. | $184.59 | 2021 | |
| Amgen INC. | $159.68 | 2019-2024 | Repatha |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $101.53 | 2019-2024 | Farxiga, Brilinta |
| Alnylam Pharmaceuticals INC. | $95.52 | 2022-2023 | Onpattro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $91.90 | 2022-2025 | Aveir, Jot Dx, Mitraclip |
| Atricure, INC. | $83.03 | 2023-2024 | |
| Astellas Pharma US INC | $77.91 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $74.54 | 2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $63.41 | 2022-2025 | Optimizer |
| Medtronic, INC. | $56.83 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $54.55 | 2023 | Inpefa |
| Lundbeck LLC | $35.77 | 2020 | |
| Esperion Therapeutics, INC. | $35.55 | 2024 | Nexletol |
| 3b Medical, INC. | $29.29 | 2024 | Luna |
| Medtronic Vascular, INC. | $22.88 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.21 | 2019 | |
| Novo Nordisk INC | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijaya Koka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.